1. Signaling Pathways
  2. Immunology/Inflammation
  3. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9904
    Atezolizumab
    Inhibitor 98.98%
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
    Atezolizumab
  • HY-P9902
    Pembrolizumab
    Inhibitor 99.06%
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
    Pembrolizumab
  • HY-16141
    Cilengitide
    Inhibitor 99.80%
    Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers.
    Cilengitide
  • HY-19991
    BMS-1
    Inhibitor 99.56%
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
    BMS-1
  • HY-P9903
    Nivolumab
    Inhibitor 99.63%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    Nivolumab
  • HY-155959
    PD-1/PD-L1-IN-33
    Inhibitor 99.57%
    PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity.
    PD-1/PD-L1-IN-33
  • HY-P10091
    CD24/Siglec-10 blocking peptide, CSBP
    Inhibitor 99.59%
    CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell.
    CD24/Siglec-10 blocking peptide, CSBP
  • HY-108730A
    Avelumab (anti-PD-L1)
    Inhibitor
    Avelumab (anti-PD-L1) is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
    Avelumab (anti-PD-L1)
  • HY-19745
    BMS-202
    Inhibitor 99.39%
    BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
    BMS-202
  • HY-78695
    JQ-1 (carboxylic acid)
    Inhibitor 99.82%
    JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.
    JQ-1 (carboxylic acid)
  • HY-P9919
    Durvalumab
    Inhibitor 99.60%
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
    Durvalumab
  • HY-100022
    Tomivosertib
    Inhibitor 99.92%
    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance.
    Tomivosertib
  • HY-P99145
    Anti-Mouse PD-L1 Antibody (10F.9G2)
    Inhibitor 99.53%
    Anti-Mouse PD-L1 Antibody is an anti-mouse PD-L1.html" class="link-product" target="_blank">PD-L1 IgG2b antibody inhibitor derived from host rat.
    Anti-Mouse PD-L1 Antibody (10F.9G2)
  • HY-108730
    Avelumab
    Inhibitor 99.30%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
    Avelumab
  • HY-P99144
    Anti-Mouse PD-1 Antibody (RMP1-14)
    Inhibitor 98.52%
    Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG1 antibody inhibitor.
    Anti-Mouse PD-1 Antibody (RMP1-14)
  • HY-P9903A
    Nivolumab (anti-PD-1)
    Inhibitor 99.20%
    Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    Nivolumab (anti-PD-1)
  • HY-P9902A
    Pembrolizumab (anti-PD-1)
    Inhibitor 99.90%
    Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1.
    Pembrolizumab (anti-PD-1)
  • HY-B0008
    Sulindac
    Modulator 99.81%
    Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.
    Sulindac
  • HY-101093
    CA-170
    Inhibitor 99.39%
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes.
    CA-170
  • HY-P99052
    Tislelizumab
    Inhibitor
    Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer.
    Tislelizumab
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity